Rapid Classification of Sarcomas Using Methylation Fingerprint: A Pilot Study.

classification copy-number machine learning methylation nanopore sarcoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Aug 2023
Historique:
received: 25 07 2023
revised: 14 08 2023
accepted: 16 08 2023
medline: 26 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

Sarcoma classification is challenging and can lead to treatment delays. Previous studies used DNA aberrations and machine-learning classifiers based on methylation profiles for diagnosis. We aimed to classify sarcomas by analyzing methylation signatures obtained from low-coverage whole-genome sequencing, which also identifies copy-number alterations. DNA was extracted from 23 suspected sarcoma samples and sequenced on an Oxford Nanopore sequencer. The methylation-based classifier, applied in the nanoDx pipeline, was customized using a reference set based on processed Illumina-based methylation data. Classification analysis utilized the Random Forest algorithm and t-distributed stochastic neighbor embedding, while copy-number alterations were detected using a designated R package. Out of the 23 samples encompassing a restricted range of sarcoma types, 20 were successfully sequenced, but two did not contain tumor tissue, according to the pathologist. Among the 18 tumor samples, 14 were classified as reported in the pathology results. Four classifications were discordant with the pathological report, with one compatible and three showing discrepancies. Improving tissue handling, DNA extraction methods, and detecting point mutations and translocations could enhance accuracy. We envision that rapid, accurate, point-of-care sarcoma classification using nanopore sequencing could be achieved through additional validation in a diverse tumor cohort and the integration of methylation-based classification and other DNA aberrations.

Identifiants

pubmed: 37627196
pii: cancers15164168
doi: 10.3390/cancers15164168
pmc: PMC10453223
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Israel Science Foundation
ID : 2279/22 and 3099/22

Références

J Negat Results Biomed. 2011 May 31;10:7
pubmed: 21627842
Mass Spectrom Rev. 2020 Mar;39(1-2):55-82
pubmed: 29889312
Stem Cell Investig. 2014 Oct 27;1:18
pubmed: 27358864
Cancer Treat Rev. 2021 Sep;99:102259
pubmed: 34311246
Neuropathol Appl Neurobiol. 2023 Feb;49(1):e12856
pubmed: 36269599
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Pathologica. 2021 Apr;113(2):70-84
pubmed: 33179614
J Cross Cult Gerontol. 1997 Dec;12(4):373-85
pubmed: 14617926
Nat Commun. 2022 Jun 15;13(1):3405
pubmed: 35705560
Am J Surg Pathol. 2017 Jul;41(7):941-949
pubmed: 28346326
Virchows Arch. 2020 Jan;476(1):109-119
pubmed: 31802230
Microorganisms. 2021 Dec 16;9(12):
pubmed: 34946199
Genes Chromosomes Cancer. 2022 Jun;61(6):346-355
pubmed: 35388566
Acta Neuropathol. 2017 Nov;134(5):691-703
pubmed: 28638988
Dev Growth Differ. 2019 Jun;61(5):316-326
pubmed: 31037722
J Clin Invest. 2013 Oct;123(10):4170-81
pubmed: 24018558
Cell Growth Differ. 1993 Dec;4(12):1065-70
pubmed: 8117620
Front Genet. 2021 May 26;12:672804
pubmed: 34122526
Nat Rev Cancer. 2003 Apr;3(4):253-66
pubmed: 12671664
Sarcoma. 1997;1(1):17-22
pubmed: 18521196
Lancet. 2018 Sep 1;392(10149):777-786
pubmed: 30100054
Am J Surg Pathol. 2016 Mar;40(3):313-23
pubmed: 26685084
Monogr Pathol. 1996;38:37-64
pubmed: 8744274
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Int J Cancer. 1995 Oct 20;64(5):342-6
pubmed: 7591308
ESMO Open. 2020 Oct;5(5):e000914
pubmed: 33082266
Nat Methods. 2017 Apr;14(4):407-410
pubmed: 28218898
Nat Commun. 2022 Jun 15;13(1):3406
pubmed: 35705558
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242

Auteurs

Aviel Iluz (A)

Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Myriam Maoz (M)

Oncology Department, Sharett Institute of Oncology, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Nir Lavi (N)

Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
Department of Military Medicine and "Tzameret", Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Hanna Charbit (H)

Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Omer Or (O)

Orthopedic Department, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Noam Olshinka (N)

Orthopedic Department, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Jonathan Abraham Demma (JA)

Surgical Department, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Mohammad Adileh (M)

Surgical Department, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Marc Wygoda (M)

Radiotherapy Institute, Sharett Institute of Oncology, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Philip Blumenfeld (P)

Radiotherapy Institute, Sharett Institute of Oncology, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Masha Gliner-Ron (M)

Radiology Department, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Yusef Azraq (Y)

Radiology Department, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Joshua Moss (J)

Oncology Department, Sharett Institute of Oncology, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Tamar Peretz (T)

Oncology Department, Sharett Institute of Oncology, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Amir Eden (A)

Department of Genetics, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Aviad Zick (A)

Oncology Department, Sharett Institute of Oncology, Hadassah Medical Organization and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Iris Lavon (I)

Leslie and Michael Gaffin Center for Neuro-Oncology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.
Agnes Ginges Center for Human Neurogenetics, Department of Neurology, Hadassah Medical Center and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190501, Israel.

Classifications MeSH